UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 297

Sortiert nach

High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL

Leukemia, 2023-02, Vol.37 (2), p.422-432

2023

Volltextzugriff (PDF)

Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma

Leukemia, 2007-10, Vol.21 (10), p.2227-2230

2007

Volltextzugriff (PDF)

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report

Leukemia, 2013-05, Vol.27 (5), p.1174-1177

2013

Volltextzugriff (PDF)

New roles for B cell receptor associated kinases: when the B cell is not the target

Leukemia, 2019-03, Vol.33 (3), p.576-587

2019

Volltextzugriff (PDF)

Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma

Leukemia, 2019-10, Vol.33 (10), p.2429-2441

2019

Volltextzugriff (PDF)

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

Leukemia, 2013-09, Vol.27 (9), p.1902-1909

2013

Volltextzugriff (PDF)

A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma

Leukemia, 2021-10, Vol.35 (10), p.2994-2997

2021

Volltextzugriff (PDF)

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma

Leukemia, 2021-07, Vol.35 (7), p.2108-2113

2021

Volltextzugriff (PDF)

Treatment resistance in diffuse large B-cell lymphoma

Leukemia, 2021-08, Vol.35 (8), p.2151-2165

2021

Volltextzugriff (PDF)

Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study

Leukemia, 2020-10, Vol.34 (10), p.2794-2797

2020

Volltextzugriff (PDF)

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

Leukemia, 2014-12, Vol.28 (12), p.2367-2375

2014

Volltextzugriff (PDF)

Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice

Leukemia, 2015-04, Vol.29 (4), p.947-957

2015

Volltextzugriff (PDF)

Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL

Leukemia, 2023-10, Vol.37 (10), p.2006-2016

2023

Volltextzugriff (PDF)

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Leukemia, 2019-04, Vol.33 (4), p.884-892

2019

Volltextzugriff (PDF)

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia

Leukemia, 2019-10, Vol.33 (10), p.2531-2535

2019

Volltextzugriff (PDF)

Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies

Leukemia, 2023-04, Vol.37 (4), p.864-876

2023

Volltextzugriff (PDF)

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

Leukemia, 2015-07, Vol.29 (7), p.1578-1586

2015

Volltextzugriff (PDF)

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells

Leukemia, 2010-10, Vol.24 (10), p.1760-1768

2010

Volltextzugriff (PDF)

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Leukemia, 2020-08, Vol.34 (8), p.2184-2197

2020

Volltextzugriff (PDF)

Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells

Leukemia, 2017-07, Vol.31 (7), p.1593-1602

2017

Volltextzugriff (PDF)

Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1

Leukemia, 2015-08, Vol.29 (8), p.1702-1712

2015

Volltextzugriff (PDF)

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma

Leukemia, 2011-09, Vol.25 (9), p.1502-1509

2011

Volltextzugriff (PDF)

1 – 25 von 297

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieLeukemia

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(297)
Mit Volltextzugriff
(281)

Publikationsform

Artikel
(297)

Sprache

Englisch
(297)
Japanisch
(38)

Erscheinungsjahr

n.n

Thema

Humans
(289)
Hematology
(284)
Oncology
(284)
Life Sciences & Biomedicine
(282)
Science & Technology
(282)
Leukemia
(202)
Biological And Medical Sciences
(161)
Medical Sciences
(161)
Hematologic And Hematopoietic Diseases
(148)
Lymphocytes B
(145)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(144)
Male
(136)
Female
(134)
Lymphoma
(133)
Lymphatic Leukemia
(126)
Chronic Lymphocytic Leukemia
(110)
Middle Aged
(102)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(100)
Patients
(97)
Aged
(92)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Nexis Uni
(297)
EZB Free E-Journals
(297)
Journals@Ovid Ovid Full Text
(297)
North East Research Libraries Nature Academic Titles
(297)
MEDLINE
(294)
IngentaConnect Journals
(108)
IngentaConnect Journals
(13)
Wiley Online Library
(1)
Wiley Online Library Full Collection 2018
(1)
Single Journals
(1)

5 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Molecular Plant-Microbe Interactions
(1)

Menü

Weitere Dienste

Einstellungen

High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL

Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report

New roles for B cell receptor associated kinases: when the B cell is not the target

Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma

Treatment resistance in diffuse large B-cell lymphoma

Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice

Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia

Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells

Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma

Aktive Filter

Suchergebnisse filtern